| Literature DB >> 19323831 |
Saulius Svagzdys1, Vaiva Lesauskaite, Dainius Pavalkis, Irena Nedzelskiene, Darius Pranys, Algimantas Tamelis.
Abstract
BACKGROUND: The extent of angiogenesis is an important prognostic factor for colorectal carcinoma, however, there are few studies concerning changes in angiogenesis with radiotherapy (RTX). Our aim was to investigate changes in tumor angiogenesis influenced by radiotherapy to assess the prognostic value of angiogenesis the microvessel density (MVD) in overall survival after radiotherapy.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19323831 PMCID: PMC2666763 DOI: 10.1186/1471-2407-9-95
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
Figure 1The "hot spot" (original magnification ×10). MVD is 133 microvessel/mm2.
Clinical Data of Patient Groups Investigated
| Treatment Groups | |||
|---|---|---|---|
| No RTX | Short RTX | Long RTX | |
| Age M ± SE, years | 71.2 ± 1.2 | 66.0 ± 2.3 | 67.6 ± 1.6 |
| Sex, % | |||
| Male | 45.6 | 43.8 | 28.6 |
| Female | 54.4 | 56.3 | 71.4 |
| Tumor, % | |||
| pT1/T2 | 22.8 | 37.5 | 35.7 |
| pT3/T4 | 77.2 | 62.5 | 64.3 |
| Lymph node metastases (pN), % | |||
| Absent | 50.9 | 56.3 | 75 |
| Present | 49.1 | 43.7 | 25 |
| Histological grade (pG), % | |||
| Very well/well | 66.7 | 37.5 | 60.7 |
| Moderate/poor | 33.3 | 62.5 | 39.3 |
| Mortality Rate, % | 42.1 | 18.8 | 39.3 |
Figure 2Differences of mean ± SE of MVD (microvessel/mm2) in untreated (no RTX), short term (short RTX) and long term RTX (long RTX) groups. F = 6.726; df = 2; p* = 0.002, p# = 0.034.
Microvessel density (MVD) in relation to gender, T, N and tumor differentiation grade in the long term RTX group.
| MVD M ± SE (microvessel/mm2) | p | |
|---|---|---|
| Gender | ||
| Male | 131,46 ± 10.2 | 0,48 |
| Female | 136,07 ± 8.9 | |
| Tumor | ||
| pT1/T2 | 145,9 ± 14,2 | 0,38 |
| pT3/T4 | 128,56 ± 7,4 | |
| Lymph node metastases pN | ||
| Absent | 134.4 ± 8,8 | 0,48 |
| Present | 135.9 ± 10,1 | |
| Histological grade pG | ||
| Very well/well | 134,4 ± 7,6 | 0,33 |
| Moderate/poor | 135,3 ± 13,7 | |
Figure 3Distribution between mean ± SE of MVD (microvessel/mm2) and survival in untreated (no RTX), short term (short RTX) and long term RTX (long RTX) groups.
Clinical Data of the Patients who received a long course of radiotherapy
| Survived | Deceased | p | |
|---|---|---|---|
| Age M ± SE, years | 67.5 ± 1.9 | 67.8 ± 2.9 | 0.64 |
| MVD M ± SE, microvessel/mm2 | 117.6 ± 5.8 | 161.2 ± 11.6 | 0.001 |
| Sex, % | |||
| Male | 35.3 | 18.2 | 0.3 |
| Female | 64.7 | 81.8 | |
| Tumor, % | |||
| pT1/T2 | 41.2 | 27.3 | 0.45 |
| pT3/T4 | 58.8 | 72.7 | |
| Lymph node metastases (pN), % | |||
| Absent | 88.2 | 54.5 | 0.044 |
| Present | 11.8 | 45.5 | |
| Histological grade (pG), % | |||
| Very well/well | 64.7 | 54.5 | 0.59 |
| Moderate/poor | 35.3 | 45.5 | |
Figure 4Diagram of ROC curves for patients who received long course of radiotherapy. Area 84.2%; p = 0.003.
Figure 5Overall survival in subjects with a cut-off <130 versus cut-off >130. Log rank test: p = 0.001.
Multivariate Cox proportional hazard analysis for mortality
| Relative risk (B) | 95% CI for Exp(B) | p | |
|---|---|---|---|
| MVD (130 ir >) | 1953.047 | 14.816–257444.0 | 0.002 |
| Age | 0.96 | 0.864–1.066 | 0.446 |
| Gender | 17.92 | 1.243–258.432 | 0.034 |
| Tumor | 111.618 | 2.578–4833.392 | 0.014 |
| Lymph node metastases | 3.34 | 0.293–38.061 | 0.331 |
| Histological grade | 127.407 | 2.774–5852.496 | 0.013 |